Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Women included in this study are undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART) and present with signs of moderate risk of developing OHSS.
No data to be entered.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Placebo Comparator | Daily Tablets Dosing |
|
| 2 | Experimental | Daily Tablets Dose |
|
| 3 | Experimental | Daily Tablets Dosing |
|
| 4 | Experimental | Daily Tablets Dosing |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Norprolac | Drug | Placebo |
| |
| Norprolac |
| Measure | Description | Time Frame |
|---|---|---|
| OHSS | 41 days after hCG injection |
Not provided
Not provided
Inclusion Criteria
Exclusion Criteria
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Development Support | Ferring Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| IVI Barcelona, Ronda General Mitre, 14 | Barcelona | 08017 | Spain | |||
| IVI Bilbao, Paseo Landabarri, 1 |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33851429 | Derived | Tang H, Mourad SM, Wang A, Zhai SD, Hart RJ. Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2021 Apr 14;4(4):CD008605. doi: 10.1002/14651858.CD008605.pub4. | |
| 20139430 | Derived | Busso C, Fernandez-Sanchez M, Garcia-Velasco JA, Landeras J, Ballesteros A, Munoz E, Gonzalez S, Simon C, Arce JC, Pellicer A. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Hum Reprod. 2010 Apr;25(4):995-1004. doi: 10.1093/humrep/deq005. Epub 2010 Feb 6. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D016471 | Ovarian Hyperstimulation Syndrome |
| ID | Term |
|---|---|
| D010049 | Ovarian Diseases |
| D000291 | Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C046650 | quinagolide |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
Quinagolide |
|
| Norprolac | Drug | Quinagolide |
|
| Norprolac | Drug | Quinagolide |
|
| Leioa-Bizkaia |
| 48940 |
| Spain |
| IVI Madrid, Santiago de Compostela, 88 | Madrid | 28035 | Spain |
| IVI Murcia, Navegante Macías del Poyo, 5, Edificio Delfín-Barrio La Flota | Murcia | 30007 | Spain |
| IVI Sevilla, Avda. República Argentina, 58 | Seville | 41011 | Spain |
| IVI Valencia, Plaza de la Policía Local, 3 | Valencia | 46015 | Spain |
| IVI Vigo, Plaza Francisco Fernández del Riego, 7 (Plaza Elíptica) | Vigo (Pontevedra) | 36203 | Spain |
| D005261 |
| Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
| D006058 | Gonadal Disorders |
| D004700 | Endocrine System Diseases |